Evidence map›Paper›PMID 38355518›Full record

ArticleMicrobial cell factories2024

The recombinant L-lysine α-oxidase from the fungus Trichoderma harzianum promotes apoptosis and necrosis of leukemia CD34 + hematopoietic cells.

Mariana do Nascimento Costa, Thiago Aparecido Silva, Dimitrius Santiago Passos Simões Fróes Guimarães, Rafael Ricci-Azevedo, Felipe Roberti Teixeira, Leonardo Reis Silveira, Marcelo Damário Gomes, Vítor Marcel Faça, Eduardo Brandt de Oliveira, Rodrigo T Calado and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial cell factories, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. The Induction of L-lysine-α-Oxidase fromAvicenna journal of medical biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mariana do Nascimento CostaDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Thiago Aparecido SilvaDepartment of Cell Biology and Molecular and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Dimitrius Santiago Passos Simões Fróes GuimarãesObesity and Comorbidities Research Center, Institute of Biology, University of Campinas, Campinas, SP, Brazil.
Rafael Ricci-AzevedoDepartment of Cell Biology and Molecular and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Felipe Roberti TeixeiraDepartment of Genetics and Evolution, Center of Biological and Health Sciences, Federal University of São Carlos, São Carlos, SP, Brazil.
Leonardo Reis SilveiraObesity and Comorbidities Research Center, Institute of Biology, University of Campinas, Campinas, SP, Brazil.
Marcelo Damário GomesDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Vítor Marcel FaçaDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Eduardo Brandt de OliveiraDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Rodrigo T CaladoDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Roberto N SilvaDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. rsilva@fmrp.usp.br.
Universidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BRUniversidade Federal de São Carlos · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/11655-4
6 · The paper itself

Abstract

backgroundIn hematologic cancers, including leukemia, cells depend on amino acids for rapid growth. Anti-metabolites that prevent their synthesis or promote their degradation are considered potential cancer treatment agents. Amino acid deprivation triggers proliferation inhibition, autophagy, and programmed cell death. L-lysine, an essential amino acid, is required for tumor growth and has been investigated for its potential as a target for cancer treatment. L-lysine α-oxidase, a flavoenzyme that degrades L-lysine, has been studied for its ability to induce apoptosis and prevent cancer cell proliferation. In this study, we describe the use of L-lysine α-oxidase (LO) from the filamentous fungus Trichoderma harzianum for cancer treatment.

resultsThe study identified and characterized a novel LO from T. harzianum and demonstrated that the recombinant protein (rLO) has potent and selective cytotoxic effects on leukemic cells by triggering the apoptotic cascade through mitochondrial dysfunction.

conclusionsThe results support future translational studies using the recombinant LO as a potential drug for the treatment of leukemia.

Indexed as

HypocrealesLeukemiaNeoplasmsTrichodermaApoptosisHumansLysineNecrosisLysineCancer treatmentLeukemiaL-lysine α-oxidaseTrichoderma harzianum

Identifiers

PMID38355518
PMCPMC10865671
OpenAlexW4391822022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.